Nature Reviews. Drug Discovery最新文献_第3页

FDA new drug approvals in Q3 2024 美国食品和药物管理局 2024 年第三季度批准的新药

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-10-10 DOI: 10.1038/d41573-024-00166-5

Paul Verdin

引用次数: 0

Reply to ‘Bayesian approaches in drug development: continuing the virtuous cycle’ 对 "药物开发中的贝叶斯方法：继续良性循环 "的答复

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-10-10 DOI: 10.1038/s41573-024-01054-8

Stephen J. Ruberg

引用次数: 0

Bayesian approaches in drug development: continuing the virtuous cycle 药物开发中的贝叶斯方法：继续良性循环

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-10-10 DOI: 10.1038/s41573-024-01052-w

Wilmar Igl, John Constant

引用次数: 0

Tumour cells get a dendritic cell makeover 树突状细胞改造肿瘤细胞

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-10-08 DOI: 10.1038/d41573-024-00168-3

M. Teresa Villanueva

引用次数: 0

mRNA vaccines for infectious diseases — advances, challenges and opportunities 用于传染病的 mRNA 疫苗--进展、挑战和机遇

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-10-04 DOI: 10.1038/s41573-024-01042-y

Norbert Pardi, Florian Krammer

{"title":"mRNA vaccines for infectious diseases — advances, challenges and opportunities","authors":"Norbert Pardi, Florian Krammer","doi":"10.1038/s41573-024-01042-y","DOIUrl":"10.1038/s41573-024-01042-y","url":null,"abstract":"The concept of mRNA-based vaccines emerged more than three decades ago. Groundbreaking discoveries and technological advancements over the past 20 years have resolved the major roadblocks that initially delayed application of this new vaccine modality. The rapid development of nucleoside-modified COVID-19 mRNA vaccines demonstrated that this immunization platform is easy to develop, has an acceptable safety profile and can be produced at a large scale. The flexibility and ease of antigen design have enabled mRNA vaccines to enter development for a wide range of viruses as well as for various bacteria and parasites. However, gaps in our knowledge limit the development of next-generation mRNA vaccines with increased potency and safety. A deeper understanding of the mechanisms of action of mRNA vaccines, application of novel technologies enabling rational antigen design, and innovative vaccine delivery strategies and vaccination regimens will likely yield potent novel vaccines against a wide range of pathogens. Following the success of the COVID-19 vaccines, mRNA vaccines have now entered development for a wide range of infectious diseases. This Review discusses mRNA vaccine design considerations, delivery strategies and mechanisms of action, assessing mRNA vaccines currently in development for various viruses, bacteria and parasites. The challenges, limitations and opportunities facing next-generation mRNA vaccines are considered.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"23 11","pages":"838-861"},"PeriodicalIF":122.7,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142374248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A viral–lipid hybrid delivery system for genetic therapies 用于基因疗法的病毒-脂质混合输送系统

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-10-03 DOI: 10.1038/d41573-024-00165-6

Katie Kingwell

引用次数: 0

FDA approves first monoclonal antibody for COPD 美国食品和药物管理局批准首个用于治疗慢性阻塞性肺病的单克隆抗体

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-10-01 DOI: 10.1038/d41573-024-00164-7

Asher Mullard

引用次数: 0

Therapeutic targeting of senescent cells in the CNS 中枢神经系统衰老细胞的治疗靶点

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-09-30 DOI: 10.1038/s41573-024-01033-z

Markus Riessland, Methodios Ximerakis, Andrew A. Jarjour, Bin Zhang, Miranda E. Orr

{"title":"Therapeutic targeting of senescent cells in the CNS","authors":"Markus Riessland, Methodios Ximerakis, Andrew A. Jarjour, Bin Zhang, Miranda E. Orr","doi":"10.1038/s41573-024-01033-z","DOIUrl":"10.1038/s41573-024-01033-z","url":null,"abstract":"Senescent cells accumulate throughout the body with advanced age, diseases and chronic conditions. They negatively impact health and function of multiple systems, including the central nervous system (CNS). Therapies that target senescent cells, broadly referred to as senotherapeutics, recently emerged as potentially important treatment strategies for the CNS. Promising therapeutic approaches involve clearing senescent cells by disarming their pro-survival pathways with ‘senolytics’; or dampening their toxic senescence-associated secretory phenotype (SASP) using ‘senomorphics’. Following the pioneering discovery of first-generation senolytics dasatinib and quercetin, dozens of additional therapies have been identified, and several promising targets are under investigation. Although potentially transformative, senotherapies are still in early stages and require thorough testing to ensure reliable target engagement, specificity, safety and efficacy. The limited brain penetrance and potential toxic side effects of CNS-acting senotherapeutics pose challenges for drug development and translation to the clinic. This Review assesses the potential impact of senotherapeutics for neurological conditions by summarizing preclinical evidence, innovative methods for target and biomarker identification, academic and industry drug development pipelines and progress in clinical trials. With ageing global populations, cellular senescence is gaining increasing attention as a therapeutic target. In their Review, Orr and colleagues discuss ongoing research into senescence in the central nervous system, including promising targets and drugs in development that aim to clear senescent cells or modulate their senescence-associated secretory phenotype.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"23 11","pages":"817-837"},"PeriodicalIF":122.7,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142329544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting undruggable GTPases 靶向不可药用 GTPases

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-09-27 DOI: 10.1038/d41573-024-00158-5

Sarah Crunkhorn

引用次数: 0

FDA approves first two drugs for rare Niemann–Pick disease 美国食品和药物管理局批准首批两种治疗罕见尼曼-皮克病的药物

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-09-27 DOI: 10.1038/d41573-024-00162-9

Asher Mullard

引用次数: 0